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in the progression of vascular calcification.4 Accumulation 
of oxidized low-density lipoprotein (oxLDL) in the vascular 
wall stimulates the development of atherosclerosis and 
vascular calcification.5
Osteonectin is a calcium-binding protein involved in bone 
formation6 that binds to hydroxyapatite.7 Osteonectin is 
expressed by the cells in the vascular wall, specifically 
during calcification of atherosclerotic plaques.8 This protein 
plays an important role in atherogenesis and may be a 
biomarker of atherosclerosis and calcinosis in coronary 
arteries.9 Bone sialoprotein (BSP) also is involved in the 
initiation of atherosclerosis. Microarray analysis reveals that 
BSP is overexpressed in human carotid plaques.10
Although the role of oxLDL in the progression of 
atherosclerosis has been suggested in the literature, little 
is known about the effect of oxLDL on extracellular matrix 
proteins involved in vascular calcification. Hence, research 
on the cause of vascular calcification may be useful in 
preventing atherosclerosis. In this study, we examined 
the ability of oxLDL to induce osteonectin and BSP, 2 
extracellular matrix proteins involved in intravascular 
mineralization.
Cardiovascular disease is the most common cause of death 
in industrialized countries. Atherosclerosis is characterized 
by lesions in the arterial intima leading to narrowing of 
the vessel lumen.1 Vascular calcification, the pathologic 
deposition of calcium phosphate in blood vessels and 
valves, is generally observed in atherosclerosis.2 Oxidative 
stress activates genes that lead to increased deposition of 
extracellular matrix proteins,3 which are an important factor 
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ABSTRACT
Background: Oxidative stress has been associated with the 
progression of atherosclerosis and activation of genes that lead to 
increased deposition of proteins in the extracellular matrix. Bone 
sialoprotein (BSP) and osteonectin are proteins involved in the initiation 
and progression of vascular calcification. 
Objective: To investigate the effect of oxidized low-density lipoprotein 
on osteonectin and BSP expression in human aorta vascular smooth 
muscle cells (HA/VSMCs).
Methods: We treated HA/VSMCs with oxidized low-density lipoprotein 
(oxLDL) and measured the relative expression of osteonectin and BSP 
genes using the real-time polymerase chain reaction (PCR) method. 
We investigated the protein levels produced by each gene using the 
western blotting technique.
Results: oxLDL increased osteonectin and BSP levels (mean [SD], 
9.1 [2.1]–fold and 4.2 [0.75]–fold, respectively) after 48 hours. 
The western blotting results also confirmed the increased levels of 
osteonectin and BSP. 
Conclusion: oxLDL may enhance vascular calcification by promoting 
the expression of osteonectin and BSP.
Keywords: atherosclerosis, vascular calcification, oxidized low-density 
lipoprotein, bone sialoprotein, osteonectin, smooth muscle cells
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Materials and Methods
Cell Culture and Treatment
We purchased human aorta vascular smooth muscle cells 
(HA/VSMCs) from the Pasteur Institute of Iran, Tehran. 
We maintained VSMCs in F12K media containing 0.05 
mg/mL ascorbic acid; 0.01 mg/mL insulin; 0.01 mg/
mL transferrin; 10 ng/mL sodium selenite; 0.03 mg/mL 
endothelial cell growth supplement; fetal bovine serum to a 
final concentration of 10%; 4-(2-Hydroxyethyl)-1-piperazine 
ethanesulfonic acid [HEPES] to a final concentration of 
10 mmol; tetradecyl sulfate, ethanol, and saline (TES) to 
a final concentration of 10 mmol; 100 U/mL penicillin; 
100 U/mL streptomycin; and 0.01% amphotericin B. Cells 
were incubated in a humidified atmosphere of 5% CO2 to 
95% air at 37°C. The cells that we used underwent 3 to 
7 passages and VSMC calcification was induced by the 
presence of 10 mmol β-glycerophosphate.
We seeded HA/VSMCs into a 12-well plate at a density 
of approximately 10,000 cells per well. When the cells 
achieved approximately 80% confluence, we changed 
the media to media containing 80 µg/mL oxLDL; Cells 
were incubated for 24 and 48 hours. Control cells were 
cultured in media containing β-glycerophosphate without 
oxLDL.
Real-Time Polymerase Chain Reaction 
(RT-PCR) Analysis 
Total RNA from the cell line was extracted using Biozol 
extraction fluid (BIOZOL Total RNA Extraction Reagent, 
BioFlux, Japan). We reverse transcribed a total of 0.3 µg of 
total RNA using the complementary DNA (cDNA) synthesis 
kit (Thermo Fisher Scientific Inc., Waltham, MA). Real-
time PCR (RT-PCR) was performed using the RotoGene 
system (Corbett Research, Sydney, Australia) and the 
SYBR green (Thermo Fisher Scientific Inc.) methods 
using primers (Table 1) for osteonectin and BSP genes 
(NM_003118.3 and NM_004967.3, respectively). Products 
were amplified as follows: initial enzyme activation at 94°C 
for 5 minutes, then 40 cycles of 95°C for 15 seconds, 59°C 
for 20 seconds, and 72°C for 30 seconds. Quantitation 
of data was by the comparative CT (ΔΔCT) method that 
uses expression of the glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) gene (NM_002046.5) as an 
endogenous reference.
Western Blot Analysis
For western blotting from cell culture, we washed cells 
twice with cold phosphate-buffered saline (PBS) and 
lysed them in ice-cold 6× radioimmune precipitation 
assay (RIPA) buffer. We incubated the homogenate 
in lysis buffer for 30 minutes and then centrifuged 
it at 12,000 g for 10 minutes at 4°C. Supernatants 
were collected as whole-cell lysates for western 
blotting. We measured protein concentration using a 
spectrophotometric method (NanoDrop 2000, Thermo 
Fisher Scientific) at A280. Equal amounts of protein from 
cell lysates were mixed with Laemmli buffer, boiled for 
5 minutes, and separated with 10% sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE). 
The gels were transferred to polyvinylidene difluoride 
(PVDF) membranes in Tris-glycine buffer for 2 hours at 
120 Volts (V). We blocked the membranes with 5% nonfat 
dry milk in Tris-buffered saline, 0.1% Tween-20 tryptic 
soy broth (Aurion, Wageningen, Netherlands) overnight 
at 4°C. The membranes were incubated with PBS, rabbit 
antiosteonectin polyclonal antibody (2 μg/mL) (Abcam 
Plc, Cambridge, England) and  anti-BSP antibody (1 
μg/mL) (Abcam Plc) for 2 hours at room temperature. 
After washing, the membranes were incubated with 
goat anti–rabbit immunoglobulin G (IgG) horseradish 
peroxidase conjugate (Abcam Plc) diluted 1:10,000 for 
90 minutes at room temperature. Finally, we incubated 
the membranes with 3, 3′-5, 5′-Tetramethylbenzidine (BM 
Blue, F. Hoffman–La Roche, Ltd., Basel, Switzerland) and 
peroxidase substrate solution at room temperature until 
the developed bands were of desired intensity. Cell lysates 
were detected on a separate membrane with actin as a 
loading control.
Statistical Analysis
Statistical analysis included the nonparametric Kruskal-
Wallis test and pair-wise comparisons among groups 
Table 1. Primer Sequences and Product Length
Gene Primer Sequences (5’-3’)
Product 
Length, bp
Osteonectina
   Forward TCTTCCCTGTACACTGGCAGTTC 73
   Reverse AGCTCGGTGTGGGAGAGGTA
BSPb
   Forward TGCCTTGAGCCTGCTTCCT 79
   Reverse CTGAGCAAAATTAAAGCAGTCTTCA
GAPDHc  
   Forward ACACCCACTCCTCCACCTTTG 112
   Reverse TCCACCACCCTGTTGCTGTAG
BSP, bone sialoprotein; GADPH, Glyceraldehyde 3-phosphate dehydrogenase.  
a NM_003118.3 
b NM_004967.3 
c NM_002046.5
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via the Mann-Whitney test. We performed all statistical 
analyses using Graph Pad Prism5 software (GraphPad 
Software, Inc., La Jolla, CA). We considered P <.05 to be 
significant.
Results
Effect of oxLDL on Osteonectin Expression 
After treatment of VSMCs with 80 µg/ml oxLDL, 
osteonectin expression at 24 hours and 48 hours was 
increased (mean [SD], 1.4 [0.3]–fold and 9.1 [2.1]–fold, 
respectively) compared with the control group. The oxLDL 
had no significant effect on osteonectin gene expression 
after 24 hours; however, we observed a significant increase 
after 48 hours of treatment (P <.05).  
The messenger-RNA (mRNA) level (Figure 1A) and protein-
expression level (Figure 1B) of osteonectin showed a 
time-dependent increase after oxLDL treatment. Also, 
treatment of HA/VSMC with oxLDL yielded 35-kDa protein 
after 48 hours (Figure 1B). These results show that oxLDL 
upregulated the expression of the osteonectin gene.
Effect of oxLDL on BSP Expression
After treating VSMCs with 80 µg/ml oxLDL, we detected 
the mRNA- and protein-expression levels of BSP via 
quantitative RT-PCR and western blot assay (Figure 2). 
The result showed that oxLDL increased BSP expression 
(mean [SD], 1.5 [0.39]–fold and 4.2 [0.75]–fold after 24 
and 48 hours, respectively. Overall treatment after 48 
hours was significant (P <.05) (Figure 2). Beta-actin 
(42 kDa) was used as an internal control to standardize 
the protein loading in western blotting. These results 
suggest that oxLDL may promote BSP upregulation in 
VSMCs and therefore could have an effect on vascular 
calcification.
Discussion
It is clear that atherosclerotic calcification is a regulated 
process that is similar to bone formation. Many bone-
related proteins are involved in this process. Also, the 
results of previous studies11,12 have shown the role of oxLDL 
in VSMC mineralization. In addition, 2 studies13,14 have 
demonstrated localization of osteoblast-differentiation 
factors in calcified atherosclerotic lesions.
VSMCs have a contractile phenotype and express 
proteins that inhibit mineralization. However, in 
atherosclerosis, a transition of VSMCs toward the 
osteoblastic phenotype occurs, and these cells express 
promoters of calcification including osteonectin, 
osteocalcin, alkaline phosphatase, and BSP. An increase 
in the factors that promote calcification and a decrease 
in the inhibitory factors cause atherosclerosis to occur.15 
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Figure 1
The effect of oxidized low-density lipoprotein (oxLDL) on osteonectin expression in human aorta vascular smooth muscle cells (HA/
VSMCs). A, Osteonectin messenger RNA (mRNA) expression compared with the control material after treatment with oxLDL using real-
time polymerase chain reaction. Data are expressed as mean (SD) for the 3 independent experiments. The * indicates P <.05. B, Results 
of protein expression levels in VSMCs by western blot analysis against control (β-actin) protein after treatment.
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In the present study, we show that oxLDL increases 
the expression of osteonectin, which is a promoter 
of calcification. Another study16 has also shown 
overexpression of osteopontin and alkaline phosphatase 
in response to oxidative stress. Ragino et al9 showed that 
osteonectin was correlated with certain key biomarkers 
of atherosclerosis, such as oxLDL, and suggested 
that osteonectin can serve as a new biomarker of 
atherosclerosis and calcinosis of coronary arteries.
In our study, oxLDL increased BSP expression, suggesting 
that BSP is involved in vascular calcification. Another 
study17 also reported that acetylated low-density 
lipoprotein (LDL) increased expression of alkaline 
phosphatase and BSP. The results of this study may 
suggest that modified lipoproteins stimulate calcification 
by enhancing osteogenic differentiation of VSMCs.17
In contrast, the results of a study18 suggest that BSP 
is involved in the inhibition of arterial calcification;18 
however, the potential of BSP to nucleate 
hydroxyapatite suggests that BSP may act as activator 
of calcification.19,20 BSP can act as a nucleator of 
crystal formation. Nevertheless, the ability of bone-
related proteins to promote or inhibit calcification depends 
on the environment of the expression,21 which suggests 
that BSP may act as activator of calcification. 
Because oxidative stress plays an important role in the 
development of atherosclerosis and the induction of 
vascular calcification,5,22 understanding its mechanism 
of action may help prevent the development of 
atherosclerosis. Antioxidant therapy might have beneficial 
effects on the reduction of vascular calcification.
The results of this study establish a direct connection 
between bone-related protein expression and oxLDL in 
the development of calcification in VSMCs, and the role 
of oxLDL in promotion of calcification, and foam-cell 
formation in atherosclerosis. Future studies are needed 
to clarify the molecular mechanisms that induce the 
expression of the BSP and osteonectin.
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